Meeting
2023 ASCO Annual Meeting
Neoadjuvant nivolumab alone or in combination with relatlimab or ipilimumab in resectable head and neck squamous cell carcinoma (HNSCC).
Authors
Robert L. Ferris
Hillman Cancer Center, Pittsburgh, PA
Robert L. Ferris , William E. Gooding , Simion I. Chiosea , Umamaheswar Duvvuri , Seungwon Kim , Mark Kubik , Shaum Sridharan , Moon Jung Fenton , Heath Devin Skinner , Zahra Rahman Kelly , Housaiyin Li , Lazar Vujanovic , Dan Paul Zandberg
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT04080804
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 6018)
DOI
10.1200/JCO.2023.41.16_suppl.6018
Abstract #
6018
Poster Bd #
10
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A phase 2 study to determine the pathological (path) response to neoadjuvant nivolumab (nivo) and relatlimab (rela) in high-risk stage II cutaneous melanoma: NeoReNi II.
First Author: Maria Gonzalez
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Assessment of complete pathologic response after neoadjuvant immunotherapy for MSI-H gastrointestinal cancers.
First Author: Kruti Bhagirath Vora
Poster
2022 ASCO Annual Meeting
LAG3 transcriptomic expression correlates with high levels of PD-1, PD-L1, PD-L2, and CTLA-4 checkpoints and with high tumor mutational burden across cancers.
First Author: Jacob J. Adashek
Poster
2022 ASCO Annual Meeting
Neoadjuvant nivolumab, ipilimumab, and celecoxib in MMR-proficient and MMR-deficient colon cancers: Final clinical analysis of the NICHE study.
First Author: Yara L. Verschoor